Development of coated tubes RIA for serum T3 (tri-iodothyronine) for production scale.
A coating procedure that could provide immobilization of antibodies, with increased binding capacity, that is cost effective, simple, robust, and appropriate for production scale application, is described. This coating approach of T3 antibodies to the polystyrene tubes has been systematically investigated to determine its utility for the development of coated tube Radioimmunoassay (RIA) for T3 in human serum. Further, the results obtained by the developed coating procedure are found to be comparable with those obtained by the "gold standard," the liquid phase RIA for T3. The coating procedure is completed in three major steps, each step involving an overnight incubation. The normal rabbit gamma-globulins are physically adsorbed onto the polystyrene tubes and incubated. After washing, a second antibody (goat anti-rabbit antiserum) is added and incubated. To this antigen specific antibody is added (T3 antibody produced in rabbit) and further incubated. Finally, the non-specific sites on the tubes are saturated by the blocking solution. The concentration of normal rabbit globulin, titers of second antibody and T3 antibody, and time required for coating are optimized to arrive at a suitable coating protocol. The coated tubes were evaluated for precision, reproducibility, and stability. Various parameters such as total reaction volume, incubation time and temperature, total number and volume of washings, concentration of 8-anilino-1-naphthalene sulfonic acid (ANS), and quantity of tracer per tube are optimized to arrive at a suitable standard curve. The optimized assay is validated for the quality control parameters such as intra- and inter-assay variations, recovery, and parallelism. The developed coated tubes assay had an assay range of 0.3-4.8 ng/mL with a sensitivity of 0.3 ng/mL at 90% B/B0. Batch to batch variation in coating was < 10%. The coated tubes were stable up to 1 year, which is adequate for production scale.
Karir
T
T
Radiopharmaceuticals Programme, Board of Radiation and Isotope Technology, Department of Atomic Energy, Vashi, Navi Mumbai, India.
Samuel
G
G
Sivaprasad
N
N
Meera
V
V
Samuel
G
G
Meera
V
V
Pillai
M R A
MR
D000818:Animals; D000906:Antibodies / Q000276:immunology; D006801:Humans; D011817:Rabbits; D011863:Radioimmunoassay / Q000295:instrumentation / Q000379:methods*; D015203:Reproducibility of Results; D017186:Titrimetry; D014284:Triiodothyronine / Q000097:blood* / Q000276:immunology*; D005719:gamma-Globulins / Q000276:immunology
D000906:Antibodies; D005719:gamma-Globulins; D014284:Triiodothyronine